A novel glaucoma approach: Stem cell regeneration of the trabecular meshwork.

Animals Glaucoma / pathology Humans Induced Pluripotent Stem Cells Intraocular Pressure Mesenchymal Stem Cells Regeneration Trabecular Meshwork
Glaucoma Stem cells Trabecular meshwork regeneration

Journal

Progress in retinal and eye research
ISSN: 1873-1635
Titre abrégé: Prog Retin Eye Res
Pays: England
ID NLM: 9431859

Informations de publication

Date de publication:
09 2022
Historique:
received: 19 09 2021
revised: 20 03 2022
accepted: 24 03 2022
pubmed: 11 4 2022
medline: 14 9 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

Glaucoma is the leading cause of global irreversible blindness, necessitating research for new, more efficacious treatment options than currently exist. Trabecular meshwork (TM) cells play an important role in the maintenance and function of the aqueous outflow pathway, and studies have found that there is decreased cellularity of the TM in glaucoma. Regeneration of the TM with stem cells has been proposed as a novel therapeutic option by several reports over the last few decades. Stem cells have the capacity for self-renewal and the potential to differentiate into adult functional cells. Several types of stem cells have been investigated in ocular regenerative medicine: tissue specific stem cells, embryonic stem cells, induced pluripotent stem cells, and adult mesenchymal stem cells. These cells have been used in various glaucoma animal models and ex vivo models and have shown success in IOP homeostasis and TM cellularity restoration. They have also demonstrated stability without serious side effects for a significant period of time. Based on current knowledge of TM pathology in glaucoma and existing literature regarding stem cell regeneration of this tissue, we propose a human clinical study as the next step in understanding this potentially revolutionary treatment paradigm. The ability to protect and replace TM cells in glaucomatous eyes could change the field forever.

Identifiants

DOI: 10.1016/j.preteyeres.2022.101063 PMID: 35398015 PMC: PMC9464663
pubmed: 35398015
pii: S1350-9462(22)00023-4
doi: 10.1016/j.preteyeres.2022.101063
pmc: PMC9464663
mid: NIHMS1796472
pii:
doi:

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101063

Subventions

Organisme : NEI NIH HHS
ID : R01 EY025643
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY030071
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY031710
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Authors report no relevant conflicts of interest.

Références

J Clin Invest. 2011 Sep;121(9):3542-53
pubmed: 21821918
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Arch Ophthalmol. 2004 Oct;122(10):1492-7
pubmed: 15477461
Cell Transplant. 2008;17(10-11):1103-13
pubmed: 19181205
Invest Ophthalmol Vis Sci. 2011 Jun 23;52(7):4506-15
pubmed: 21498611
Ophthalmol Retina. 2019 Oct;3(10):850-859
pubmed: 31248784
Stem Cells. 2015 Mar;33(3):751-61
pubmed: 25377070
J Ocul Pharmacol Ther. 2016 Jun;32(5):253-60
pubmed: 27183473
Exp Eye Res. 2018 Jun;171:164-173
pubmed: 29526795
Eye Vis (Lond). 2019 Oct 17;6:31
pubmed: 31641682
Exp Gerontol. 2005 Aug-Sep;40(8-9):745-8
pubmed: 16051457
Invest Ophthalmol Vis Sci. 1982 Jan;22(1):45-56
pubmed: 7056624
Circ Res. 2017 Aug 18;121(5):496-498
pubmed: 28819039
Drug Discov Today. 2012 Mar;17(5-6):253-60
pubmed: 22493784
Vet Ophthalmol. 2004 Jan-Feb;7(1):23-7
pubmed: 14738503
Stem Cells. 2013 Jun;31(6):1136-48
pubmed: 23495088
Trends Cell Biol. 2002 Nov;12(11):502-8
pubmed: 12446111
Stem Cells Int. 2019 Apr 9;2019:9628536
pubmed: 31093291
Nat Neurosci. 2018 Oct;21(10):1370-1379
pubmed: 30250265
Cell Stem Cell. 2012 Jan 6;10(1):9-10; author reply 10-1
pubmed: 22226349
Invest Ophthalmol Vis Sci. 2012 May 04;53(5):2495-500
pubmed: 22562850
Nature. 2019 Sep 2;:
pubmed: 32868921
Cell Reprogram. 2018 Dec;20(6):329-336
pubmed: 31251672
Neurosci Lett. 2013 Apr 29;541:43-8
pubmed: 23403103
J Tissue Eng Regen Med. 2018 Mar;12(3):695-704
pubmed: 28556530
Commun Biol. 2018 Dec 6;1:216
pubmed: 30534608
Cell Transplant. 2019 Jul;28(7):801-812
pubmed: 31018669
Biomolecules. 2021 Aug 24;11(9):
pubmed: 34572471
Arch Med Res. 2021 Jan;52(1):93-101
pubmed: 32977984
Anat Histol Embryol. 2002 Jun;31(3):169-86
pubmed: 12479360
J Neurosci Methods. 2001 Oct 15;111(1):39-48
pubmed: 11574118
Stem Cells. 2009 Jul;27(7):1635-42
pubmed: 19544455
Radiology. 2018 Dec;289(3):604-615
pubmed: 30299232
Surv Ophthalmol. 1990 Jul-Aug;35(1):67-73
pubmed: 2204129
Cancer Res. 2005 Apr 15;65(8):3035-9
pubmed: 15833829
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096604
Invest Ophthalmol Vis Sci. 2021 Mar 1;62(3):18
pubmed: 33704361
Sci Rep. 2018 Aug 16;8(1):12251
pubmed: 30115953
Invest Ophthalmol Vis Sci. 1979 Oct;18(10):1043-9
pubmed: 383640
Am J Transl Res. 2014 Jan 15;6(2):114-8
pubmed: 24489990
Stem Cells Dev. 2020 Mar 1;29(5):290-300
pubmed: 31854234
Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1447-58
pubmed: 18385062
Invest Ophthalmol Vis Sci. 1981 Nov;21(5):714-27
pubmed: 7298275
Hum Mol Genet. 2007 Mar 15;16(6):609-17
pubmed: 17317787
Sci Rep. 2020 Feb 19;10(1):2905
pubmed: 32076077
Restor Neurol Neurosci. 2020;38(3):223-237
pubmed: 32310198
Mol Cell. 2017 May 4;66(3):306-319
pubmed: 28475867
J Ocul Pharmacol Ther. 1998 Feb;14(1):57-66
pubmed: 9493783
Prog Brain Res. 2015;220:241-56
pubmed: 26497794
Patient Prefer Adherence. 2011;5:441-63
pubmed: 22003282
Oncotarget. 2016 Jul 26;7(30):46913-46923
pubmed: 27391437
Expert Opin Ther Targets. 2017 Nov;21(11):1037-1050
pubmed: 28952395
J Transl Med. 2018 Nov 7;16(1):304
pubmed: 30404629
Cell Stem Cell. 2011 Aug 5;9(2):97-102
pubmed: 21816361
Mol Vis. 2005 Sep 26;11:816-24
pubmed: 16205623
Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):E3492-500
pubmed: 27274060
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4809-4817
pubmed: 28973327
J Ocul Pharmacol Ther. 2000 Feb;16(1):19-27
pubmed: 10673127
N Engl J Med. 2017 Mar 16;376(11):1047-1053
pubmed: 28296617
News Physiol Sci. 2003 Oct;18:205-9
pubmed: 14500801
Ophthalmology. 1984 Jun;91(6):580-95
pubmed: 6540429
Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1450-9
pubmed: 23341019
Stem Cell Res Ther. 2016 Dec 1;7(1):178
pubmed: 27906070
Curr Ophthalmol Rep. 2019 Jun;7(2):80-88
pubmed: 31316866
Ophthalmology. 2012 May;119(5):979-86
pubmed: 22349567
Int Ophthalmol. 2019 Dec;39(12):2913-2922
pubmed: 31309439
Stem Cells Int. 2018 Sep 4;2018:3038565
pubmed: 30254681
Biochem Biophys Res Commun. 2020 Aug 20;529(2):411-417
pubmed: 32703444
Stem Cells Int. 2019 Nov 14;2019:2754927
pubmed: 31814830
Am J Ophthalmol. 2017 Apr;176:61-69
pubmed: 27993589
Exp Eye Res. 2006 Jun;82(6):959-67
pubmed: 16310191
Cell Stem Cell. 2020 Oct 1;27(4):523-531
pubmed: 33007237
N Engl J Med. 2017 Mar 16;376(11):1038-1046
pubmed: 28296613
Exp Eye Res. 2006 Aug;83(2):390-400
pubmed: 16631164
Invest Ophthalmol Vis Sci. 2014 Oct 08;55(11):7065-72
pubmed: 25298418
Cell Stem Cell. 2016 Feb 4;18(2):253-61
pubmed: 26669899
Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):935-40
pubmed: 24448264
Arch Neurol. 2010 Oct;67(10):1187-94
pubmed: 20937945
Medicine (Baltimore). 2014 Dec;93(29):e355
pubmed: 25546695
PLoS Med. 2010 Mar 30;7(3):e1000245
pubmed: 20361020
Biomedicines. 2019 Nov 30;7(4):
pubmed: 31801246
Arch Ophthalmol. 2010 Mar;128(3):338-43
pubmed: 20212205
PLoS One. 2013;8(1):e55170
pubmed: 23383095
Invest Ophthalmol Vis Sci. 1980 Feb;19(2):126-36
pubmed: 6766124
Exp Eye Res. 2006 Apr;82(4):545-57
pubmed: 16386733
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):94-101
pubmed: 24401029
Elife. 2021 Mar 30;10:
pubmed: 33783352
NPJ Regen Med. 2020 Sep 11;5:15
pubmed: 32983575
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Am J Ophthalmol. 1989 Jan 15;107(1):1-6
pubmed: 2912110
Exp Eye Res. 2017 May;158:3-12
pubmed: 27448987
Invest Ophthalmol Vis Sci. 2014 Oct 16;55(11):7499-507
pubmed: 25324280
Exp Eye Res. 2009 Apr;88(4):747-51
pubmed: 19061887
Invest Ophthalmol Vis Sci. 2012 Mar 21;53(3):1566-75
pubmed: 22297497
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2054-2062
pubmed: 28384726
Elife. 2021 Jan 28;10:
pubmed: 33506763
Cancer Res. 2009 Jul 1;69(13):5331-9
pubmed: 19509230
Sci Rep. 2018 Apr 11;8(1):5848
pubmed: 29643342
Stem Cells Dev. 2020 Jan 1;29(1):49-61
pubmed: 31680626
FASEB J. 2020 May;34(5):7160-7177
pubmed: 32259357
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2051-9
pubmed: 19933193
Arch Immunol Ther Exp (Warsz). 2008 Jan-Feb;56(1):1-8
pubmed: 18250975
Sci Rep. 2018 Feb 12;8(1):2814
pubmed: 29434243
Mol Vis. 2008 Aug 18;14:1513-6
pubmed: 18728789
Sci Rep. 2021 Dec 31;11(1):24518
pubmed: 34972817
Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4244-53
pubmed: 19357352
Ophthalmology. 1984 Jun;91(6):564-79
pubmed: 6462622
Nat Med. 2013 Aug;19(8):998-1004
pubmed: 23921754
Stem Cell Res Ther. 2015 Sep 16;6:177
pubmed: 26377305
PLoS One. 2016 May 05;11(5):e0154412
pubmed: 27149523
Stem Cell Res Ther. 2016 Aug 11;7(1):107
pubmed: 27515308
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1714-1722
pubmed: 30651311
PLoS One. 2012;7(10):e47559
pubmed: 23133515
J Clin Med. 2020 Jul 13;9(7):
pubmed: 32668747
Am J Ophthalmol. 1973 Mar;75(3):365-83
pubmed: 4633234
Science. 2007 Dec 21;318(5858):1917-20
pubmed: 18029452
Invest Ophthalmol Vis Sci. 2012 May 04;53(5):2462-3
pubmed: 22562840
Surv Ophthalmol. 2015 Mar-Apr;60(2):93-105
pubmed: 25132498

Auteurs

Sara J Coulon (SJ)

Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, USA.

Joel S Schuman (JS)

Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, USA; Center for Neural Science, College of Arts and Science, New York University, New York, NY, USA; Departments of Biomedical Engineering and Electrical and Computer Engineering, New York University Tandon School of Engineering, Brooklyn, NY, USA; Department of Physiology and Neuroscience, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, USA. Electronic address: joel.schuman@nyu.edu.

Yiqin Du (Y)

Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Mohammad Reza Bahrani Fard (MR)

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, GA, USA.

C Ross Ethier (CR)

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, GA, USA.

W Daniel Stamer (WD)

Departments of Ophthalmology and Biomedical Engineering, Duke University, Durham, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › A novel glaucoma approach: Stem cell...
questionsmedicales.fr › Maladies de l'oeil › Hypertension oculaire › Glaucome › A novel glaucoma approach: Stem cell...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A novel glaucoma approach: Stem cell...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches pluripotentes › Cellules souches pluripotentes induites › A novel glaucoma approach: Stem cell...
questionsmedicales.fr › Phénomènes physiologiques oculaires › Pression intraoculaire › A novel glaucoma approach: Stem cell...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches multipotentes › Cellules souches mésenchymateuses › A novel glaucoma approach: Stem cell...
questionsmedicales.fr › Phénomènes biologiques › Régénération › A novel glaucoma approach: Stem cell...
questionsmedicales.fr › Organes des sens › Oeil › Pôle antérieur du bulbe oculaire › Réseau trabéculaire de la sclère › A novel glaucoma approach: Stem cell...